The percentage of CD19-B220+CD5+CD1d+ Bregs tended to increase in mice with MASLD (Fig. S2C) and significantly increased in mice with HCC/NRASG12V/p19Arf-/- (Fig. S2O). This evidence concerns the gene CD5 and hepatocellular carcinoma.